The potential role of IL‐33/ST2 signaling in fibrotic diseases
Review on the biological characteristics of IL‐33 and the role of the IL‐33/ST2 signaling pathway in various fibrotic diseases. IL‐33, a new member of the IL‐1F, is widely expressed throughout the body and can be up‐regulated by stimulation with proinflammatory factors. It has been identified as a f...
Gespeichert in:
Veröffentlicht in: | Journal of leukocyte biology 2015-07, Vol.98 (1), p.15-22 |
---|---|
Hauptverfasser: | , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 22 |
---|---|
container_issue | 1 |
container_start_page | 15 |
container_title | Journal of leukocyte biology |
container_volume | 98 |
creator | Gao, Qiaoyan Li, Yan Li, Mingcai |
description | Review on the biological characteristics of IL‐33 and the role of the IL‐33/ST2 signaling pathway in various fibrotic diseases.
IL‐33, a new member of the IL‐1F, is widely expressed throughout the body and can be up‐regulated by stimulation with proinflammatory factors. It has been identified as a functional ligand for the plasma membrane receptor complex that is a heterodimer consisting of membrane‐bound ST2L, which is a member of the IL‐1R family, and IL‐1RAcP. IL‐33 is crucial for the induction of Th2 immune responses. Additionally, under other circumstances, it can also act as an endogenous danger signal. Recently, many studies have demonstrated that IL‐33 may be related to the development and progression of fibrotic diseases. It has proinflammatory effects in some fibrotic diseases but has anti‐inflammatory effects in others. In this review, the biologic characteristics of IL‐33 and the role of the IL‐33/ST2 signaling pathway in various fibrotic diseases will be discussed. We hope this overview will provide new insights for the treatment of these diseases. |
doi_str_mv | 10.1189/jlb.3RU0115-012R |
format | Article |
fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1808637660</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1808637660</sourcerecordid><originalsourceid>FETCH-LOGICAL-c4865-1f584ceeda880c9c1c692a8e7dac05c32721847fc2b13836e92bac51c90535323</originalsourceid><addsrcrecordid>eNqFkLtOwzAUhi0EouWyM6GMLCnn-MSOs3ERV0VCgjJbjuOAqzQpcSrExiPwjDwJQS2snf7l-7_hY-wIYYKostNZXUzo8RkQRQzIH7fYGDNSMcmUttkY0gRjkQCM2F4IMwAgLmGXjbhQavhnY3Y2fXXRou1d03tTR11bu6itorv8-_OL6PRpyqPgXxpT--Yl8k1U-aJre2-j0gdnggsHbKcydXCH691nz9dX08vbOH-4ubs8z2ObKClirIRKrHOlUQpsZtHKjBvl0tJYEJZ4ylElaWV5gaRIuowXxgq0GQgSxGmfnay8i659W7rQ67kP1tW1aVy7DBoVKEmplLAZlRmhSonjgMIKtV0bQucqvej83HQfGkH_JtZDYr1OrH8TD5fjtX1ZzF35f_hrOgBiBbz72n1sFOr7_AIABf0AvnmGeg</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1693187321</pqid></control><display><type>article</type><title>The potential role of IL‐33/ST2 signaling in fibrotic diseases</title><source>Wiley Online Library - AutoHoldings Journals</source><source>MEDLINE</source><source>Oxford University Press Journals All Titles (1996-Current)</source><source>EZB-FREE-00999 freely available EZB journals</source><source>Alma/SFX Local Collection</source><creator>Gao, Qiaoyan ; Li, Yan ; Li, Mingcai</creator><creatorcontrib>Gao, Qiaoyan ; Li, Yan ; Li, Mingcai</creatorcontrib><description>Review on the biological characteristics of IL‐33 and the role of the IL‐33/ST2 signaling pathway in various fibrotic diseases.
IL‐33, a new member of the IL‐1F, is widely expressed throughout the body and can be up‐regulated by stimulation with proinflammatory factors. It has been identified as a functional ligand for the plasma membrane receptor complex that is a heterodimer consisting of membrane‐bound ST2L, which is a member of the IL‐1R family, and IL‐1RAcP. IL‐33 is crucial for the induction of Th2 immune responses. Additionally, under other circumstances, it can also act as an endogenous danger signal. Recently, many studies have demonstrated that IL‐33 may be related to the development and progression of fibrotic diseases. It has proinflammatory effects in some fibrotic diseases but has anti‐inflammatory effects in others. In this review, the biologic characteristics of IL‐33 and the role of the IL‐33/ST2 signaling pathway in various fibrotic diseases will be discussed. We hope this overview will provide new insights for the treatment of these diseases.</description><identifier>ISSN: 0741-5400</identifier><identifier>EISSN: 1938-3673</identifier><identifier>DOI: 10.1189/jlb.3RU0115-012R</identifier><identifier>PMID: 25881899</identifier><language>eng</language><publisher>United States</publisher><subject>cardiac fibrosis ; Fibrosis - metabolism ; hepatic fibrosis ; Humans ; Interleukin-1 Receptor-Like 1 Protein ; Interleukin-33 ; Interleukins - physiology ; pulmonary fibrosis ; Receptors, Cell Surface - physiology ; Receptors, Interleukin - metabolism ; Signal Transduction - physiology ; skin fibrosis</subject><ispartof>Journal of leukocyte biology, 2015-07, Vol.98 (1), p.15-22</ispartof><rights>2015 Society for Leukocyte Biology</rights><rights>Society for Leukocyte Biology.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c4865-1f584ceeda880c9c1c692a8e7dac05c32721847fc2b13836e92bac51c90535323</citedby><cites>FETCH-LOGICAL-c4865-1f584ceeda880c9c1c692a8e7dac05c32721847fc2b13836e92bac51c90535323</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1189%2Fjlb.3RU0115-012R$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1189%2Fjlb.3RU0115-012R$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>314,780,784,1417,27924,27925,45574,45575</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/25881899$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Gao, Qiaoyan</creatorcontrib><creatorcontrib>Li, Yan</creatorcontrib><creatorcontrib>Li, Mingcai</creatorcontrib><title>The potential role of IL‐33/ST2 signaling in fibrotic diseases</title><title>Journal of leukocyte biology</title><addtitle>J Leukoc Biol</addtitle><description>Review on the biological characteristics of IL‐33 and the role of the IL‐33/ST2 signaling pathway in various fibrotic diseases.
IL‐33, a new member of the IL‐1F, is widely expressed throughout the body and can be up‐regulated by stimulation with proinflammatory factors. It has been identified as a functional ligand for the plasma membrane receptor complex that is a heterodimer consisting of membrane‐bound ST2L, which is a member of the IL‐1R family, and IL‐1RAcP. IL‐33 is crucial for the induction of Th2 immune responses. Additionally, under other circumstances, it can also act as an endogenous danger signal. Recently, many studies have demonstrated that IL‐33 may be related to the development and progression of fibrotic diseases. It has proinflammatory effects in some fibrotic diseases but has anti‐inflammatory effects in others. In this review, the biologic characteristics of IL‐33 and the role of the IL‐33/ST2 signaling pathway in various fibrotic diseases will be discussed. We hope this overview will provide new insights for the treatment of these diseases.</description><subject>cardiac fibrosis</subject><subject>Fibrosis - metabolism</subject><subject>hepatic fibrosis</subject><subject>Humans</subject><subject>Interleukin-1 Receptor-Like 1 Protein</subject><subject>Interleukin-33</subject><subject>Interleukins - physiology</subject><subject>pulmonary fibrosis</subject><subject>Receptors, Cell Surface - physiology</subject><subject>Receptors, Interleukin - metabolism</subject><subject>Signal Transduction - physiology</subject><subject>skin fibrosis</subject><issn>0741-5400</issn><issn>1938-3673</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2015</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFkLtOwzAUhi0EouWyM6GMLCnn-MSOs3ERV0VCgjJbjuOAqzQpcSrExiPwjDwJQS2snf7l-7_hY-wIYYKostNZXUzo8RkQRQzIH7fYGDNSMcmUttkY0gRjkQCM2F4IMwAgLmGXjbhQavhnY3Y2fXXRou1d03tTR11bu6itorv8-_OL6PRpyqPgXxpT--Yl8k1U-aJre2-j0gdnggsHbKcydXCH691nz9dX08vbOH-4ubs8z2ObKClirIRKrHOlUQpsZtHKjBvl0tJYEJZ4ylElaWV5gaRIuowXxgq0GQgSxGmfnay8i659W7rQ67kP1tW1aVy7DBoVKEmplLAZlRmhSonjgMIKtV0bQucqvej83HQfGkH_JtZDYr1OrH8TD5fjtX1ZzF35f_hrOgBiBbz72n1sFOr7_AIABf0AvnmGeg</recordid><startdate>201507</startdate><enddate>201507</enddate><creator>Gao, Qiaoyan</creator><creator>Li, Yan</creator><creator>Li, Mingcai</creator><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>7T5</scope><scope>H94</scope></search><sort><creationdate>201507</creationdate><title>The potential role of IL‐33/ST2 signaling in fibrotic diseases</title><author>Gao, Qiaoyan ; Li, Yan ; Li, Mingcai</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c4865-1f584ceeda880c9c1c692a8e7dac05c32721847fc2b13836e92bac51c90535323</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2015</creationdate><topic>cardiac fibrosis</topic><topic>Fibrosis - metabolism</topic><topic>hepatic fibrosis</topic><topic>Humans</topic><topic>Interleukin-1 Receptor-Like 1 Protein</topic><topic>Interleukin-33</topic><topic>Interleukins - physiology</topic><topic>pulmonary fibrosis</topic><topic>Receptors, Cell Surface - physiology</topic><topic>Receptors, Interleukin - metabolism</topic><topic>Signal Transduction - physiology</topic><topic>skin fibrosis</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Gao, Qiaoyan</creatorcontrib><creatorcontrib>Li, Yan</creatorcontrib><creatorcontrib>Li, Mingcai</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>Immunology Abstracts</collection><collection>AIDS and Cancer Research Abstracts</collection><jtitle>Journal of leukocyte biology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Gao, Qiaoyan</au><au>Li, Yan</au><au>Li, Mingcai</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>The potential role of IL‐33/ST2 signaling in fibrotic diseases</atitle><jtitle>Journal of leukocyte biology</jtitle><addtitle>J Leukoc Biol</addtitle><date>2015-07</date><risdate>2015</risdate><volume>98</volume><issue>1</issue><spage>15</spage><epage>22</epage><pages>15-22</pages><issn>0741-5400</issn><eissn>1938-3673</eissn><abstract>Review on the biological characteristics of IL‐33 and the role of the IL‐33/ST2 signaling pathway in various fibrotic diseases.
IL‐33, a new member of the IL‐1F, is widely expressed throughout the body and can be up‐regulated by stimulation with proinflammatory factors. It has been identified as a functional ligand for the plasma membrane receptor complex that is a heterodimer consisting of membrane‐bound ST2L, which is a member of the IL‐1R family, and IL‐1RAcP. IL‐33 is crucial for the induction of Th2 immune responses. Additionally, under other circumstances, it can also act as an endogenous danger signal. Recently, many studies have demonstrated that IL‐33 may be related to the development and progression of fibrotic diseases. It has proinflammatory effects in some fibrotic diseases but has anti‐inflammatory effects in others. In this review, the biologic characteristics of IL‐33 and the role of the IL‐33/ST2 signaling pathway in various fibrotic diseases will be discussed. We hope this overview will provide new insights for the treatment of these diseases.</abstract><cop>United States</cop><pmid>25881899</pmid><doi>10.1189/jlb.3RU0115-012R</doi><tpages>8</tpages><oa>free_for_read</oa></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0741-5400 |
ispartof | Journal of leukocyte biology, 2015-07, Vol.98 (1), p.15-22 |
issn | 0741-5400 1938-3673 |
language | eng |
recordid | cdi_proquest_miscellaneous_1808637660 |
source | Wiley Online Library - AutoHoldings Journals; MEDLINE; Oxford University Press Journals All Titles (1996-Current); EZB-FREE-00999 freely available EZB journals; Alma/SFX Local Collection |
subjects | cardiac fibrosis Fibrosis - metabolism hepatic fibrosis Humans Interleukin-1 Receptor-Like 1 Protein Interleukin-33 Interleukins - physiology pulmonary fibrosis Receptors, Cell Surface - physiology Receptors, Interleukin - metabolism Signal Transduction - physiology skin fibrosis |
title | The potential role of IL‐33/ST2 signaling in fibrotic diseases |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-02T06%3A55%3A51IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=The%20potential%20role%20of%20IL%E2%80%9033/ST2%20signaling%20in%20fibrotic%20diseases&rft.jtitle=Journal%20of%20leukocyte%20biology&rft.au=Gao,%20Qiaoyan&rft.date=2015-07&rft.volume=98&rft.issue=1&rft.spage=15&rft.epage=22&rft.pages=15-22&rft.issn=0741-5400&rft.eissn=1938-3673&rft_id=info:doi/10.1189/jlb.3RU0115-012R&rft_dat=%3Cproquest_cross%3E1808637660%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1693187321&rft_id=info:pmid/25881899&rfr_iscdi=true |